Echinococcosis is one of the most dangerous invasive diseases of animals and humans, that causes significant social and economic damage. Due to the localization of cysts, cystic hydatidosis is extremely difficult to treat, and it is not uncommon that surgical intervention is the only possible means. At the same time, cystic echinococcosis is a very common parasitic disease of sheep, goats, cattle, and even horses and is usually registered quite widely in regions traditionally engaged in breeding of these animal species. The work provides information on the spread of cystic echinococcosis in the Russian Federation and the main factors that cause the pathogen to circulate under agricultural conditions. Joint trends in the development of protective drugs, diagnostic test systems and chemotherapeutic drugs for this invasion, as well as technological problems that arise when creating vaccines, are analyzed. Given the current state in addressing the issue of mass vaccination of animals, a list of organizational, economic, medical, preventive and informational measures aimed at providing effective antiparasitic drugs and control methods is provided.

Objective of research: the study on tolerability and therapeutic efficacy of the complex drug Helmintal produced on the basis of two ingredients moxidectin and praziquantel. Materials and methods: In our research, we used four drug modifications: for cats and kittens weighting less than 4 kg (moxidectin 0.4 mg and praziquantel 10 mg); for cats — more than 4 kg (moxidectin 1.6 mg and praziquantel 40 mg); for dogs and puppies — less than 10 kg (moxidectin 1 mg and praziquantel 25 mg); for dogs — more than 10 kg (moxidectin 5 mg and praziquantel 125 mg.) To study the effect of the drug on the organism, three groups of clinically healthy animals were formed (5 animals per group): dogs 1 — 2 years of age with the body mass 18 — 20 kg; puppies 3 — 5 weeks of age weighting 0.8 — 1 kg; cats 1 — 2 years of age weighting 3 — 5 kg; kittens 6 — 8 weeks of age with the body mass 0.6 — 0.8 kg. The drug was given to animals orally once a day in the morning within 7 days in the following doses: the first experimental group — 0.4 mg moxidectin and praziquantel 10 mg per 1 kg of body weight (double therapeutic dose); the second group — moxidectin 1.0 mg and praziquantel 25 mg per 1 kg of body weight (five-fold therapeutic dose); the third group served as controls — the drug was not used. During the experiment, animals were monitored daily, their general health status, behavior, appetite were observed, weight and body temperature controlled. Before and 15 and 30 days after the beginning of the drug taking, several morphological and biochemical parameters of blood and urine were investigated. The study of the anthelmintic efficacy of the drug was carried out on the basis of veterinary clinics in Moscow and Moscow region. Altogether 205 cats and 209 dogs spontaneously infected were chosen for the experiment. The diagnosis and the drug efficacy were confirmed based on the clinical picture and on Fulleborn’s method used for detection of helminth eggs in animal’s feces followed by differentiation. Results and discussion: During the study on the drug tolerance it was found that the general status, mass and the body temperature of animals from experimental groups did not significantly differ from controls. Morphological and biochemical parameters of blood and urine in all animals from experimental and control groups did not differ significantly and were within the physiological norm before and after treatment. Thus, the research allows to conclude that the drug applied within 7 days at double and fivefold therapeutic doses has no adverse effect on dogs, puppies, cats and kittens. Most sick animals used in the experiment on the effectiveness of the drug, were emaciated, listless, their fur was ruffled, mucous membranes were pale; they suffered from anal itching, diarrhea and fecal retention. The drug was given after diagnosis; many dogs and cats ate it themselves, and other had no problems with eating pills due to their small size and pleasant taste. When applying the drug and throughout the experiment, no side effects and complications were observed in all animals. 10 and 20 days after giving the drug, its efficacy in the treatment of nematodosis and cestodosis of adult dogs cats as well as kittens and puppies was 100%.

Objective of research: To evaluate the tolerability of the drug, “Inspector Collar” based on Fipronil, Pyriproxyfen and Ivermectin in dogs and cats applied at a therapeutic dose and double increased therapeutic doses. Materials and methods: Research was conducted at the shelter for dogs and cats «Bano Eco» (Moscow). Effect of drug “Inspector Collar” was studied on 15 clinically healthy outbreed dogs between 2 and 6 years with the body mass of 10–14 kg and 15 clinically healthy outbreed cats between 2 and 4 years with the body mass of 2–3,5 kg, receiving complete and balanced nutrition. Animals were divided into six groups (three groups of dogs and three of cats) five animals in each group. Dogs and cats from the first experimental group had put on one collar (equivalent of single therapeutic dose) for 45 days. The second experimental group had put two collars (double therapeutic dose) for 45 days. Animals from the third (control) group did not carry collars. During the experiment, daily supervision of animals was conducted; their general health status, behavior, appetite were observed, body mass and temperature estimated. Before and 15 and 30 days after the beginning of drug application, blood and urine tests were performed to study morphological and biochemical parameters. Statistical processing of data were carried out using Student’s t-test. Results and discussion: The research results showed that the drug “Inspector Collar” is well tolerated even at double therapeutic dose. All observed indicators remained within the physiological norm.

This article describes the results of studies of the therapeutic efficacy of the drug "Helminthal Mini Syrup" in the treatment of coccidioses and nematodoses of dogs and cats. The drug contains a new combination of active ingredients, toltrazuril and moxidectin, providing a wide range of antiparasitic action against pathogens of coccidioses and intestinal nematodoses. The studies were conducted from February to August 2019 in veterinary clinics of the city of Moscow and the Moscow Region on dogs and cats naturally infested with coccidia (Eimeria spp., Isospora spp., Cystoisospora spp.), intestinal nematodes (Toxocara canis, Toxocara cati (mystax), Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala, Trichuris vulpis), and in mixed invasions. The drug was used individually orally as a single dose of 0.5 ml per 1 kg of animal weight, which corresponds to 9 mg of toltrazuril and 0.3 mg of moxidectin. 10–14 days after the use of the drug, satisfactory general condition, absence of clinical manifestations of invasions were noted, in a laboratory test of feces – helminth eggs and protozoan oocysts were absent, which confirms the high therapeutic efficacy in coccidioses, intestinal nematodoses and mixed intestinal parasitoses of dogs and cats.

We studied therapeutic and prophylactic efficacy of new drugs against ectoparasitosis in dogs and cats. New veterinary drugs for dogs and cats were developed with the combined active substances (Imidacloprid, Pyriproxyfen and Moxidectin) in the form of a spot-on solution for external application at the premises of the VNIIP – FSC VIEV. The difference between the drugs is the different content of Moxidectin – the Moxidectin content is 2.5 times higher in the drug for dogs than the drug for cats. The studies were performed on dogs and cats of different sex, age, body weight and breed spontaneously infected with pathogens of acariasis and entomosis in the settings of the Podolsk Experimental Production Base of the VNIIP – FSC VIEV and in a Moscow veterinary clinic in 2021. Experimental and control groups were formed according to the principle of analogues. The diagnosis and drug efficacy were confirmed holistically based on the anamnestic and epizootological data, clinical picture and laboratory research methods (microscopy of scraps taken from the affected areas of the skin, and examination of the coat for fleas, lice, chewing lice and ixodid ticks). Babesiosis (piroplasmosis) was excluded in the dogs. The drugs were used in the experimental group of animals in the dose range of 0.1–0.4 mL per kg of the body weight of the animal according to the Draft Instructions for Use. It was found that the drugs showed high therapeutic and prophylactic efficacy against sarcoptic mange of dogs, notoedric mange of cats, otodectic mange and entomosis of dogs and cats, as well as ixodid ticks attacking animals.